Chinese Journal of Clinical Oncology

, Volume 2, Issue 2, pp 558–562 | Cite as

The value of interferon combined with hepatic artery chemoembolization and portal vein chemotherapy in preventing a recurrence after radical resection for hepatocellular carcinoma

  • Honghao Li
  • Hongwei Zhang
  • Jie Wang
  • Erwei Song
  • Jisheng Chen
Original Article



The change of cell immune function after hepatectomy of patients suffering from hepatocellular carcinoma (HCC) is usually neglected. The aim of this study was to explore the change of T cell subsets in HCC patients after hepatectomy, and to study the value of treatment with interferon (INF) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) to prevent recurrence after radical resection of HCC.


Seventy-five HCC patients were treated with PVC and HACE at the 2nd week and 4th week after radical tumor resection. In the 2nd week after surgery, 33 pationts received INF treatment for one week. Seventy-two patients were followed up over three years. The effect of INF combined with HACE and PVC on the postoperative recurrence rate was compared with that of HACE and PVC treatment. Changes of T cell subsets in the peripheral blood were examined with labeled monoclonal antibodies before and after hepatectomy or with use of interferon. Forty cholecystolithiasis patients who received a cholecystectomy were used as controls.


CD3 + and CD4 + cells in the peripheral blood were reduced in patients with HCC. After hepatectomy, they declined further with a decrease in the CD4 +/CD8 + ratio. The values returned to pre-operative level at the 4th week after surgery. The CD3 + and CD4 + cells and the CD4 +/CD8 + ratio increased remarkably following the use of INF. The 1-, 2- and 3-year recurrent rates of patients treated with HACE, PVC and INF in combination were 0%, 6.2% and 15.6%, respectively, while those treated only with HACE and PVC were 5.0%, 12.5% and 27.5%, respectively.


Patients with HCC suffer from a marked immuno-suppression, which become ever more severe after hepatectomy. The combined use of HACE, PVC and INF is superior in decreasing the recurrent rate to the combination of only HACE and PVC.


liver neoplasm/therapy hepatectomy chemoembolization therapeutic interferon neoplasm recurrence 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Zhou XD, Yu YQ, Tang ZY, et al. Surgical treatment of recurrent hepatocellular carcinoma. Hepato-Gastroenterol. 1993; 40:333–336.Google Scholar
  2. 2.
    Li JQ, Zhang YQ, Zhang WZ, et al. The Value of Chemoembolization after resection of hepatocellular carcinoma. Chin J Oncol. 1994; 16:387–389.Google Scholar
  3. 3.
    Li HH, Ou QJ, Chen JS, et al. Combined hepatic artery chemoembolization and portal vein chemotherapy after radical hepatectomy for hepatocellular carcinoma to prevent recurrence. Chin J Oncol. 2000; 22:61–63.Google Scholar
  4. 4.
    Zhou XD, Tang ZY, Yu YQ, et al. Changing prognosis of primary liver cancer: some aspects to improve long-term survival. Chin J Oncol. 1996; 18:211–213.Google Scholar
  5. 5.
    Qin JG, Han BL, Pan SL, et al. Clinical implication of Tcell subsets and its functions in recurrence of human primary hepatocellular carcinoma. Chin J Exp Surg. 1998; 15:11–12.Google Scholar
  6. 6.
    Mao H, Zhao MF, Song WS. Change of solube interleukin 2 receptor and T lymphocytes subsets in patients with primary hepatic cancer after TAE. Chin J Clin Hepatol. 1999; 15: 48–50.Google Scholar
  7. 7.
    Lu W, Li YH, He XF, et al. Effect of dosage of anticancer agents during transcatheter arterial chemoembolization on T cell subsets in patients with hepatocellular carcinoma. J First Mil Med Univ. 2002; 22:524–526.Google Scholar
  8. 8.
    Xie LY, Pang RL, Jin YH, et al. Clinical study of immunotherapy combined with hepatic chemoembolization for liver cancer after radical surgery. J Clinic Radio. 2001; 20:308–309.Google Scholar
  9. 9.
    Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998; 82:827–835.PubMedCrossRefGoogle Scholar
  10. 10.
    Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trail of effects of interferon -a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346:1051–1055.PubMedCrossRefGoogle Scholar

Copyright information

© Chinese Anti-Cancer Association and Springer 2005

Authors and Affiliations

  • Honghao Li
    • 1
  • Hongwei Zhang
    • 1
  • Jie Wang
    • 1
  • Erwei Song
    • 1
  • Jisheng Chen
    • 1
  1. 1.Department of General SurgeryThe 2nd Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina

Personalised recommendations